Cargando…
2898. Achieving Hepatitis C SVR12 of 95% in Mono-Infected Patients with Severe Comorbidities Using Volunteer Staff and Minimal Clinic Visits and Phlebotomy
BACKGROUND: HCV is the most common chronic bloodborne infection in the United States with an estimated 3.5 million infected. With direct-acting antivirals, cure can be achieved in 8 to 12 weeks. To achieve WHO elimination targets by 2030 (>90% reduction in incidence) requires increased detection,...
Autores principales: | van der Horst, Charles M, Greenberg, Gary, Kirchgessner, Erin, Vaughn, Amanda, Alfano-Sobsey, Edie, Riggleman, Amy, Soufan, Ayat, Horner, Mandy, Nadabar, Asha, Castillo, Diana, Campbell, Elizabeth, Lynn Ledford, Sue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808893/ http://dx.doi.org/10.1093/ofid/ofz359.176 |
Ejemplares similares
-
Virus Transfer from Personal Protective Equipment to Healthcare Employees’ Skin and Clothing
por: Casanova, Lisa, et al.
Publicado: (2008) -
Phlebotomy in Excelsis
por: Curran, W.
Publicado: (1888) -
Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021) -
2898. PrEP Inequity Across Geographic, Racial and Sex Groups in a Nationwide US Veteran Cohort
por: Musoke, Lewis S, et al.
Publicado: (2023) -
Remarks on "Hepatic Phlebotomy"
por: Harley, George
Publicado: (1887)